{
    "organizations": [],
    "uuid": "94de7c85ee2e105f33d97f9b0fbdbc336ff0a9bb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neurovive-receives-fda-orphan-drug/brief-neurovive-receives-fda-orphan-drug-designation-idUSFWN1RV0BH",
    "ord_in_thread": 0,
    "title": "BRIEF-NeuroVive Receives FDA Orphan Drug Designation",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:\n* NEUROVIVE’S KL1333 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TREATMENT OF MITOCHONDRIAL DISEASES\n* ODD OPENS UP FOR MARKET EXCLUSIVITY FOR SEVEN YEARS WITHIN US FOR NEUROVIVE’S KL1333, WHEN AUTHORISED FOR MARKETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-18T15:20:00.000+03:00",
    "crawled": "2018-04-19T15:28:30.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "neurovive",
        "pharmaceutical",
        "ab",
        "neurovive",
        "kl1333",
        "receives",
        "fda",
        "orphan",
        "drug",
        "designation",
        "treatment",
        "mitochondrial",
        "disease",
        "odd",
        "open",
        "market",
        "exclusivity",
        "seven",
        "year",
        "within",
        "u",
        "neurovive",
        "kl1333",
        "authorised",
        "marketing",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}